Key result
BM 13.177 is a weak inhibitor of TXA2-mediated contractions of coronary vessels, reducing the TXA2 component of contraction by 56% at 30 mumol/L.
Population
Arachidonic acid-stimulated washed human platelets and bovine coronary arteries in an organ bath model
Comparison
BM 13.177 (4-[2--ethyl]-phenoxyacetic acid) at… vs Untreated conditions or lower concentrations
Design
Preclinical
Authors
Loading...
Does not support clinical translation of BM 13.177; leaves open vessel-specific thromboxane receptor subtypes for targeted investigation.
BM 13.177 is a weak inhibitor of TXA2-mediated contractions of coronary vessels, suggesting the presence of different thromboxane receptors in coronary vessels compared to platelets.
Verheggen et al. (1986) studied Coronary vasospasm (in vitro model). BM 13.177 was evaluated on TXA2 component of contraction. BM 13.177 is a weak inhibitor of TXA2-mediated contractions of coronary vessels, reducing the TXA2 component of contraction by 56% at 30 mumol/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: